Guilford cuts jobs in restructuring

Guilford Pharmaceuticals is cutting 38 jobs and refocusing its efforts on two products: a treatment for brain cancer and the experimental anesthesia Aquavan. Guilford said that it would continue to support the heart disease therapy Aggrastat as it sought to license, sell or partner on the treatment. But only "minimal" funds would be used to promote the drug. Aggrastat earned $12.5 million in revenue last year. Its hopes for future success lie with Aquavan, which the company believes could be submitted for approval next year.

- read this story from the AP for more on the restructuring

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.